Industry Liaison Forum (ILF)

AIM: To promote and facilitate the full contribution of the biomedical industry to the HIV response by catalysing multi-stakeholder dialogue, engagement and action to address barriers along the HIV prevention, diagnosis and care continuum.

The ILF brings "companies together in an environment where we can discuss HIV issues under a transparent mission statement of improving outcomes using pharmaceutical expertise" – ILF industry member

The Industry Liaison Forum’s (ILF’s) strategic plan for 2020-2023 highlights its commitment to further build on its unique attributes of neutrality, convening power, multi-stakeholder composition and rules of engagement to strengthen its contribution to the HIV response. To achieve this, the ILF will:

  • Engage and grow membership by continuing to act as a cross-stakeholder, neutral, safe-space platform that actively expands and engages its membership base in order to foster connections, dialogue and action.
  • Accelerate priority areas by addressing barriers along the HIV prevention, diagnosis and care continuum.
  • Communicate perspectives by publishing and promoting its perspectives to advance the global HIV response.

Interested in joining? Industry access to the ILF is through the IAS Corporate Partnership Programme, a mechanism to inform and support collaboration and partnership between the IAS and non-industry and key industry partners. Find out more about the IAS Corporate Partnership Programme.

Interested non-industry members can contact [email protected].


Since it was established in 2001, the ILF has convened industry partners from generic pharmaceutical manufacturers and diagnostic and health-related companies, as well as non-industry and community-based organizations. Together, ILF members have brought, and continue to bring, a wealth of perspectives, expertise and knowledge in order to cross-share and contribute collaboratively to the HIV response.

Key highlights include:

  • Mobilizing stakeholders around pre-exposure prophylaxis (PrEP) as early as 2006
  • Developing and supporting a pragmatic approach to incentivize the development of priority paediatrics ARV formulations (advanced procurement policy brief), which led to the creation of the Global Accelerator for Paediatric Formulations (GAP-f), now hosted by the Clinton Health Access Initiative (CHAI)
  • Collating and sharing the Manufacturers’ Perspective on World Health Organization Prequalification of In Vitro Diagnostics (Clinical Infectious Diseases, 2018, 66:301–305)
  • Convening satellites and symposiums on treatment options (such as preventing vertical transmission of HIV), gender representation in clinical research, expanding access to viral load monitoring in resource-limited settings, addressing challenges of early infant diagnosis and point-of-care diagnostics, and more

ILF Corporate Partners

The Industry Liaison Forum would like to thank its 2021 Corporate Partners:

Gold partners

Silver partners

Bronze partners

Learn about the IAS Corporate Partnership Programme